Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome

American Journal of Gastroenterology

Volumn 106, Issue 1, 2011, Pages 166-

  Sprakes, Michael B ^a   Hamlin, P John ^a   Ford, Alexander C ^a  

^a Leeds Vascular Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

DISEASE ACTIVITY; ENTERITIS; FECES ANALYSIS; INFLAMMATION; IRRITABLE COLON; LETTER; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX;

EID: 78650974733     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.355     Document Type: Letter

References (5)

1. Keohane J, O'Mahoney C, O'Mahoney L et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation. Am J Gastroenterol 2010; 105: 1789-94.
2. Costa F, Mumolo MG, Bellini M et al. Role of fecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
3. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
4. Schoepfer AM, Trummler M, Seeholzer P et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-9.
5. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl II): II43-7.